Literature DB >> 22873127

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.

Iris Delrue1, Dieter Verzele, Annemieke Madder, Hans J Nauwynck.   

Abstract

The aim of this review is to make researchers aware of the benefits of an efficient quality control system for prediction of a developed vaccine's efficacy. Two major goals should be addressed when inactivating a virus for vaccine purposes: first, the infectious virus should be inactivated completely in order to be safe, and second, the viral epitopes important for the induction of protective immunity should be conserved after inactivation in order to have an antigen of high quality. Therefore, some problems associated with the virus inactivation process, such as virus aggregate formation, protein crosslinking, protein denaturation and degradation should be addressed before testing an inactivated vaccine in vivo.

Mesh:

Substances:

Year:  2012        PMID: 22873127     DOI: 10.1586/erv.12.38

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  51 in total

Review 1.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

2.  Detection of receptor-induced glycoprotein conformational changes on enveloped virions by using confocal micro-Raman spectroscopy.

Authors:  Xiaonan Lu; Qian Liu; Javier A Benavides-Montano; Anthony V Nicola; D Eric Aston; Barbara A Rasco; Hector C Aguilar
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

3.  Protective efficacy of inactivated Newcastle disease virus vaccines prepared in two different oil-based adjuvants.

Authors:  Oday A Aljumaili; Muhammad B Bello; Swee K Yeap; Abdul R Omar; Aini Ideris
Journal:  Onderstepoort J Vet Res       Date:  2020-09-28       Impact factor: 1.792

4.  Aβ seeds resist inactivation by formaldehyde.

Authors:  Sarah K Fritschi; Amarallys Cintron; Lan Ye; Jasmin Mahler; Anika Bühler; Frank Baumann; Manuela Neumann; K Peter R Nilsson; Per Hammarström; Lary C Walker; Mathias Jucker
Journal:  Acta Neuropathol       Date:  2014-09-06       Impact factor: 17.088

5.  Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties in ex vivo and in vivo models.

Authors:  Tuksin Jearanaiwitayakul; Panya Sunintaboon; Runglawan Chawengkittikul; Jitra Limthongkul; Panuwat Midoeng; Preamrudee Chaisuwirat; Saradee Warit; Sukathida Ubol
Journal:  Hum Vaccin Immunother       Date:  2021-04-16       Impact factor: 3.452

Review 6.  An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.

Authors:  Cielo García-Montero; Oscar Fraile-Martínez; Coral Bravo; Diego Torres-Carranza; Lara Sanchez-Trujillo; Ana M Gómez-Lahoz; Luis G Guijarro; Natalio García-Honduvilla; Angel Asúnsolo; Julia Bujan; Jorge Monserrat; Encarnación Serrano; Melchor Álvarez-Mon; Juan A De León-Luis; Miguel A Álvarez-Mon; Miguel A Ortega
Journal:  Vaccines (Basel)       Date:  2021-04-27

Review 7.  An Overview of Veterinary Viral Diseases and Vaccine Technologies.

Authors:  Alejandro Brun
Journal:  Methods Mol Biol       Date:  2022

Review 8.  Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response.

Authors:  Ecem Saygili; Ece Yildiz-Ozturk; Macauley J Green; Amir M Ghaemmaghami; Ozlem Yesil-Celiktas
Journal:  Biomicrofluidics       Date:  2021-03-23       Impact factor: 2.800

9.  BEI Inactivated Vaccine Induces Innate and Adaptive Responses and Elicits Partial Protection upon Reassortant Betanodavirus Infection in Senegalese Sole.

Authors:  Yulema Valero; José G Olveira; Carmen López-Vázquez; Carlos P Dopazo; Isabel Bandín
Journal:  Vaccines (Basel)       Date:  2021-05-04

Review 10.  Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development.

Authors:  Fouad A Abolaban; Fathi M Djouider
Journal:  Open Life Sci       Date:  2021-06-02       Impact factor: 0.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.